Future studies should focus on optimizing DHCR7-targeted inhibitors and rationally combining them with cell cycle checkpoint modulators, such as WEE1 inhibitors, or ER stress-enhancing agents to amplify tumor cell killing while minimizing toxicity. Here, WEE1 is linked to neoplasm.